TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02954874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo standard monitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03793166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04339972

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LIFUP
Description: The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
Study: NCT02580071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sheng-Yu-Tang
Description: Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)
Study: NCT04806425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline is given in same volume to normal saline group over the same duration
Study: NCT03793166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study: NCT03767374

Intervention type: PROCEDURE
Intervention: Anal swab sample
Description: Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)

Intervention type: PROCEDURE
Intervention: Anal swab sample
Description: Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
Study: NCT02411591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study: NCT02638610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet-Bonnet aesthesiometer
Description: The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface.
Study: NCT04058821

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel MRI scan - 7 days post injury
Description: * A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)
Study: NCT03767374

Intervention type: PROCEDURE
Intervention: Fecal sample
Description: Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
Study: NCT03793166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03698019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT04058821

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel MRI scan - 14 days post injury
Description: * A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI scan - 6 months post brachial plexus exploration
Description: * Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI scan - 12 months post brachial plexus exploration
Description: * Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)
Study: NCT04276662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: 1 dose of 50 mg DS-3201b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: 1 dose of 50 mg DS-3201b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: 1 dose of 50 mg DS-3201b
Study: NCT03044353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: 20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: 20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: 20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
Study: NCT00670111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insignia Plus / Ultra (Guidant/Boston Scientific)
Description: Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insignia Plus / Ultra (Guidant/Boston Scientific)
Description: Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
Study: NCT03348514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 30 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 60 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 120 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 240 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 360 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 600 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 900 mg/m^2
Description: CPX-POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 1200 mg/m^2
Description: CPX-POM
Study: NCT01873950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dofetilide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03767374

Intervention type: PROCEDURE
Intervention: Fecal sample
Description: Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)

Intervention type: OTHER
Intervention: Risk factor assessment
Description: Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization

Intervention type: OTHER
Intervention: Risk factor assessment
Description: Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
Study: NCT02842632

Intervention type: OTHER
Group type: OTHER
Intervention: theoretical test
Description: The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
Study: NCT03398772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Coaching Program
Description: Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
Study: NCT02631161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equia Forte
Description: Restoration of cavities with a Glasshybrid material (Equia Forte)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Supreme XT/Clearfil SE Bond
Description: Restoration of cavities with a composite resin based material after placing an adhesive
Study: NCT03147027

Intervention type: PROCEDURE
Intervention: VT ablation
Description: Substrate mapping for VT will be performed with the CARTO electroanatomical system.
Study: NCT02842632

Intervention type: OTHER
Group type: OTHER
Intervention: theoretical test
Description: The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study

Intervention type: OTHER
Group type: OTHER
Intervention: theoretical test
Description: The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study

Intervention type: OTHER
Group type: OTHER
Intervention: practical test
Description: The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.

Intervention type: OTHER
Group type: OTHER
Intervention: practical test
Description: The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.

Intervention type: OTHER
Group type: OTHER
Intervention: practical test
Description: The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
Study: NCT01157130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Regimen
Description: Exercise instruction
Study: NCT01960920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered diesel exhaust
Description: Mask-filtered exposure to diesel exhaust

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered diesel exhaust
Description: Mask-filtered exposure to diesel exhaust

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfiltered diesel exhaust
Description: Diesel Exhaust Inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unfiltered diesel exhaust
Description: Diesel Exhaust Inhalation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clean air
Description: No pollution and no filter mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean air
Description: No pollution and no filter mask
Study: NCT02436005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenacite
Description: Subjects will be randomized to wear the Phenacite contact lenses binocularly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phenacite
Description: Subjects will be randomized to wear the Phenacite contact lenses binocularly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects will be randomized to wear the comfilcon A contact lenses binocularly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
Study: NCT02598063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: ADV will be administered orally at a dose of 10 mg QD for 72 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
Study: NCT03527485

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11UCB-J PET Scan
Description: 11UCB-J PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11UCB-J PET Scan
Description: 11UCB-J PET Scan
Study: NCT03587493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLE ANALYSIS
Description: Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
Study: NCT01107093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDB-2914 (ulipristal acetate)
Description: single oral dose of 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study: NCT04678856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT00033917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin
Description: an anti-inflammatory drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline
Study: NCT03004118

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutridrink
Description: Liquid meal of 200ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink
Description: Liquid meal of 200ml

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High resolution manometry probe
Description: Catheter inserted via the nose into the stomach to measure intragastric pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High resolution manometry probe
Description: Catheter inserted via the nose into the stomach to measure intragastric pressure.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: perfusion catheter
Description: Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: perfusion catheter
Description: Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 4 week oral intake (daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursochol oral tablet
Description: 4 week oral intake (daily) (dose of 10.5mg/kg/day)
Study: NCT03698019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT03004118

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Duodenal fluid aspiration catheter
Description: Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal fluid aspiration catheter
Description: Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Duodenogastroscopy
Description: Catheter inserted via the mounth into the duodenum to take duodenal biopsies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenogastroscopy
Description: Catheter inserted via the mounth into the duodenum to take duodenal biopsies.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
Study: NCT02230605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mini-Mental State Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Administered Gerocognitive Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-Administered Gerocognitive Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale
Description: To be completed at the Screening Visit and at POD 90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Geriatric Depression Scale
Description: To be completed at the Screening Visit and at POD 90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Description: To be completed at the Screening Visit and at POD 90
Study: NCT03698019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery